Glenmark is the first company in India to have received the regulator’s approval for 400 mg dosage form Increased strength of FabiFlu® yet another milestone effort by Glenmark’s in-house R... Read more
Phase 3 Trial Demonstrates Statistically Significant Faster Time to Clinical Improvement with Favipiravir Treatment in Mild to Moderate COVID 19 Patients Compared to Control PUNE: Glenmark P... Read more
Endorsed by the Association of Physicians of India (API) & Hypertension Society of India (HSI) Also pledges on-ground screening of 5 million people for high BP in India One in 3 adults... Read more
Due to better yield and scale, Glenmark passes the benefits to patients by reducing the price of oral antiviral FabiFlu® by 27 % in India The new MRP is INR 75 per tab from the earlier INR 1... Read more
This is for the treatment of mild to moderate COVID-19 Manufacturing and marketing approval granted as part of the accelerated approval process, considering the emergency situation of the CO... Read more
Promising reduction in risk of severe attacks and improvement in lung function AIRZ-FF is India’s first Glycopyrronium + Formoterol + Fluticasone combination, exclusively studied in the Indi... Read more
Covid-19 patients from over 10 leading government and private hospitals in India are being enrolled for the study Trial completion and study results expected by July/August 2020 Glenmark was... Read more
2014 The Global Indian New Network (TGINN)
